Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06621602 · ClinicalTrials.gov registry record

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

A clinical trial of Parkinson Disease and REM Behavior Disorder, sponsored by CND Life Sciences.

Active
Registry status
100
Enrollment target
18
Study locations

NCT06621602 is a study of Parkinson Disease and REM Behavior Disorder that is active but no longer recruiting, run by CND Life Sciences. The registered enrollment target is 100 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 18 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06621602, a study of Parkinson Disease and REM Behavior Disorder, is active but no longer recruiting, sponsored by CND Life Sciences.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
18
Study locations

Study Summary

This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.

Conditions Studied

Parkinson Disease REM Behavior Disorder

Study Locations (18)

California

  • Parkinson's Research Centers of America - Orange County - Aliso Viejo
  • Cedars Sinai - Los Angeles
  • Parkinson's Research Centers of America - Palo Alto - Palo Alto

Arizona

  • CND Life Sciences - Scottsdale
  • Movement Disorders Center of Arizona - Scottsdale

Florida

  • Aventura Neurologic Associates, LLC - Aventura
  • Parkinson's Disease and Movement Disorders Center - Boca Raton - Boca Raton

New York

  • Parkinson's Research Centers of America - Long Island - Commack
  • University of Rochester - Rochester

Colorado

  • University of Colorado - Aurora

Georgia

  • Atlanta NeuroScience Institute ANI - Atlanta

Kansas

  • Parkinson's Disease and Movement Disorders Center at KUMC - Kansas City

Kentucky

  • Neurology Multidisciplinary Clinic at Norton Healthcare - Louisville

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-12-17
Est. Completion 2027-04

Sponsor

CND Life Sciences

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06621602

The ClinicalTrials.gov registry entry for NCT06621602 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is CND Life Sciences, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.

NCT06621602 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT06621602 about?

NCT06621602 is a clinical study titled "Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease". This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN q...

What is the current status of trial NCT06621602?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2024-12-17. Estimated completion is 2027-04.

What conditions does trial NCT06621602 study?

This clinical trial studies the following conditions: Parkinson Disease, REM Behavior Disorder.

Who is sponsoring clinical trial NCT06621602?

This trial is sponsored by CND Life Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06621602 being conducted?

This trial has 18 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

REM Behavior Disorder

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.